2-(3-hydroxy-1H-indol-2-yl)acetic acid | 119736-52-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(3-hydroxy-1H-indol-2-yl)acetic acid
• CAS: 119736-52-6
• 化学式: C₁₀H₉NO₃
• 分子量: 191.18
• InChiKey: LUCMHWVFHHFPOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  73.3
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] CALCIUM RECEPTOR ACTIVE MOLECULES
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：WO1993004373A1

  公开（公告）日：1993-03-04

  (EN) Method and composition useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more Ca2+ receptors. Novel compounds useful in these methods and compositions are also provided. The method includes administering to the patient a therapeutically effective amount of a molecule active at one or more Ca2+ receptors as an agonist or antagonist. Preferably, the molecule is able to act as either a selective agonist or antagonist at a Ca2+ receptor of one or more but not all cells chosen from the group consisting of parathyroid cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, keratinocytes, parafollicular thyroid cells and placental throphoblasts and a pharmaceutically acceptable carrier.(FR) Procédés et compositions utiles dans le traitement d'un patient présentant une maladie caractérisée par un niveau anormal d'un ou de plusieurs constituants, dont l'activité est régulée ou affectée par l'activité d'un ou de plusieurs récepteurs de Ca2+. L'invention concerne également de nouveaux composés utilisés selon ledit procédé et ladite composition. Le procédé présenté consiste à administrer au patient une quantité thérapeutiquement efficace d'une molécule agissant sur un ou plusieurs récepteurs de Ca2+ comme un agoniste ou un antagoniste. De préférence, la molécule est capable d'agir soit comme agoniste ou antagoniste sélectif sur un récepteur de Ca2+ de l'une ou de plusieurs cellules, mais non de toutes les cellules, choisies dans le groupe comprenant les cellules parathyroïdiennes, les ostéoclastes, les cellules rénales juxtaglomérulaires, les cellules rénales du tube proximal, les kératinocytes, les cellules thyroïdiennes parafolliculaires et les throphoblastes placentaires. La composition selon l'invention contient également un excipient pharmaceutiquement acceptable.

  一种用于治疗患有一种疾病的方法和组合物，该疾病的特征是其中一个或多个成分的水平异常，其活性受到一个或多个Ca2+受体的活性调节或影响。还提供了在这些方法和组合物中有用的新化合物。该方法包括向患者施用一种在一个或多个Ca2+受体上具有激动剂或拮抗剂活性的分子的治疗有效量。最好，该分子能够作为一种选择性激动剂或拮抗剂作用于来自以下组中所选的一种或多种但不是全部细胞的Ca2+受体：副甲状腺细胞、骨骼破骨细胞、近曲小管肾细胞、近端肾小管细胞、角质细胞、甲状腺滤泡旁细胞和胎盘滋养层细胞，以及一种药学上可接受的载体。
• Calcium receptor-active molecules
  申请人：Van Wagenen C. Bradford

  公开号：US20060229470A1

  公开（公告）日：2006-10-12

  The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca 2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.

  本发明涉及无机离子受体在细胞和身体过程中的不同作用。本发明特点包括：(1) 可以调节一个或多个无机离子受体活性的分子，最好是可以模拟或阻断细胞表面离子对具有无机离子受体的细胞的影响，更好的是细胞表面离子是Ca2+，对具有钙受体的细胞产生影响; (2) 无机离子受体蛋白及其片段，最好是钙受体蛋白及其片段; (3) 编码无机离子受体蛋白及其片段的核酸，最好是编码钙受体蛋白及其片段的核酸; (4) 靶向无机离子受体蛋白的抗体及其片段，最好是靶向钙受体蛋白的抗体; 以及(5) 上述分子、蛋白质、核酸和抗体的用途。
• DIAGNOSTIC TEST AND TREATMENT FOR A NEUROLOGICAL DISORDER
  申请人：Minassian Berge

  公开号：US20140187593A1

  公开（公告）日：2014-07-03

  Methods and compositions relating to diagnosing and treating a VMAT-2 deficiency disease are described. Provided are methods for screening for, diagnosing or detecting a risk of developing a VMAT-2 deficiency disease comprising detecting the presence of a VMAT-2 variant in a sample of a subject, wherein the presence of the VMAT-2 variant is indicative that the subject has a VMAT-2 deficiency disease or an increased risk of developing a VMAT-2 deficiency disease compared to an individual having wild type VMAT-2. Also provided are methods of treating a VMAT-2 deficiency disease with a dopamine agonist.

  本文描述了与诊断和治疗VMAT-2缺陷疾病相关的方法和组合物。提供了筛选、诊断或检测VMAT-2缺陷疾病发展风险的方法，包括检测受试者样本中VMAT-2变异体的存在，其中VMAT-2变异体的存在表明受试者患有VMAT-2缺陷疾病或比具有野生型VMAT-2的个体更容易发展VMAT-2缺陷疾病。还提供了使用多巴胺激动剂治疗VMAT-2缺陷疾病的方法。
• Indoxyl-beta-d-glucuronide and method for making
  申请人：QUEEN'S UNIVERSITY AT KINGSTON

  公开号：EP0284725A2

  公开（公告）日：1988-10-05

  Indoxyl-β- -glucuronide. its stable salts and analogs thereof are described, together with a process for the production thereof in which a compound of the formula: where X is halogen and R is lower alkyl is reacted with a compound of the formula: where R1 is any common carboxyl-protecting group, X, Y, Z and Q are the same or different and selected from hydrogen, halogen, trihalogenated alkene, trihalo-methyl, nitro, saturated or unsaturated alkyl and an aromatic moiety in water and methylene chloride containing an alkali hydroxide in the presence of a phase transfer catalyst, with subsequent removal of the blocking groups and conversion to the desired stable salt.

  描述了吲哚基-β-葡萄糖醛酸、其稳定盐及其类似物，以及其生产工艺，在该工艺中，式： 式中，X 为卤素，R 为低级烷基的化合物与式中的化合物反应： 其中 R1 是任何常见的羧基保护基团，X、Y、Z 和 Q 是相同或不同的，并且选自氢、卤素、三卤代烯烃、三卤代甲基、硝基、饱和或不饱和烷基和芳香族基团，在相转移催化剂存在下，在水和含有碱氢氧化物的二氯甲烷中反应，随后除去封端基团并转化为所需的稳定盐。
• Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
  申请人：Metabolon, Inc.

  公开号：US10267777B2

  公开（公告）日：2019-04-23

  Methods are described herein for small molecule biochemical profiling of an individual subject for diagnosis of a disease or disorder, facilitating diagnosis of a disease or disorder, and/or identifying an increased risk of developing a disease or disorder in the individual subject. Aberrant levels of small molecules present in a sample from an individual subject are identified and diagnostic information relevant to the individual subject is obtained based on the identified aberrant levels. The obtained diagnostic information includes one or more of an identification of at least one biochemical pathway associated with the identified subset of the small molecules having aberrant levels, an identification at least one disease or disorder associated with the identified subset of the small molecules having aberrant levels, and an identification of at least one recommended follow up test associated with the identified subset of the small molecules having aberrant levels.

  本文描述了对个体受试者进行小分子生化分析的方法，以诊断疾病或失调，促进疾病或失调的诊断，和/或确定个体受试者罹患疾病或失调的风险增加。确定个体受试者样本中存在的小分子的异常水平，并根据确定的异常水平获得与个体受试者相关的诊断信息。所获得的诊断信息包括：至少一个生化途径的鉴定，该生化途径与所鉴定的具有异常水平的小分子子集相关；至少一种疾病或紊乱的鉴定，该疾病或紊乱与所鉴定的具有异常水平的小分子子集相关；至少一种推荐的后续检测的鉴定，该检测与所鉴定的具有异常水平的小分子子集相关。